Last updated: February 15, 2026
What is the current market status of drug NDC 00121-0885?
The drug with NDC 00121-0885 is Vyvanse (lisdexamfetamine dimesylate), approved by the U.S. Food and Drug Administration (FDA) in 2007 for the treatment of ADHD and moderate to severe binge eating disorder. It holds a significant position in the stimulant medication market, particularly within the ADHD therapeutic segment.
Sales revenue for Vyvanse reached approximately $1.9 billion in 2022, representing roughly 5.5% of the total ADHD drug market, which was estimated at $35 billion globally.[1] The drug's market share is consistent among stimulant medications, favoring a broad patient base, including pediatric and adult populations.
How does Vyvanse's patent landscape influence market dynamics?
Vyvanse’s primary patent was approved in 2007, with a patent expiration date of July 2023 in the U.S.[2] This expiration opens opportunities for generic manufacturers to enter the market, increasing competition and putting downward pressure on prices.
When patents expire, the price typically declines by 30-50% within the first year due to generic entry.[3] The availability of generics in the U.S. is expected to significantly impact Vyvanse’s pricing and market share.
What are the projected price trends for Vyvanse?
Pre-Patent Expiry (Before July 2023)
- Average wholesale price (AWP): approximately $500–$600 per month for a typical dose.[4]
- Retail prices have remained stable, supported by brand loyalty and formulary coverage.
Post-Patent Expiry (After July 2023)
- Introduction of generics expected to reduce prices by 30-50% initially.[5]
- Estimated median wholesale price for generics: around $250–$350 per month, based on historical precedents for similar drugs.
- Market share is poised to shift from the brand to generics, leading to a drop in revenue for the brand version.
Long-term Outlook (Next 3-5 Years)
- Price decline: stabilization at lower levels, with potential slight increases for branded Vyvanse in niche markets or via patent extensions.
- Volume increases: increased accessibility due to lower prices may boost overall prescription volume, partially offsetting price decreases.
- Competition from other ADHD medications (e.g., Adderall, Concerta) may influence pricing.
How does the competitive landscape impact future market prices?
The key competitors include:
- Adderall XR (amphetamine/dextroamphetamine): Well-established with similar efficacy, available as a generic since 2015.
- Concerta (methylphenidate): Also has generics, with a different mechanism.
- Generic lisdexamfetamine formulations: Entry expected to erode Vyvanse’s market share.
Price competition among generics often leads to price erosion, especially if prescribing habits shift towards less costly options. Brand Vyvanse's pricing stability depends on maintaining clinical advantages or formulary exclusivity.
What are the regulatory impacts on pricing projections?
FDA’s approval pathways, including 505(b)(2) applications, may enable competitors to develop modified formulations or new molecular entities, impacting Vyvanse’s market share and price. Patent litigation or extensions could delay generics, sustain higher prices.
The U.S. Patent and Trademark Office (USPTO) has issued patent extensions for Vyvanse, possibly delaying generic entry until late 2023 or later.[6] If legal challenges extend patent protections, pricing could remain stable for a longer period.
What is the outlook for international markets?
Vyvanse is marketed in several countries under different brand names, with varying patent protections and generics availability.
- In Europe, generic versions entered markets post-2020, leading to price reductions.
- Emerging markets exhibit lower prices due to affordability and limited patent protections.
- International price adjustments follow local reimbursement and regulatory policies.
Summary of Price Projections
| Time Frame |
Price Trend |
Market Impact |
| Pre-2023 (patent maintained) |
Stable, premium to generics |
High brand revenue, limited generic competition |
| Post-2023 (patent expiration) |
Price decline of 30-50% |
Increased generic share, reduced overall revenue |
| 2024–2028 |
Stabilization at lower prices |
Volume increase may offset price erosion |
Key Takeaways
- Vyvanse's patent expiry in July 2023 introduces significant price pressure due to generic entry.
- Prices are expected to decline by 30-50% initially, with stabilization at lower levels.
- The market share shift toward generics will influence revenue projections.
- Regulatory and legal factors, including patent litigation and extensions, will shape timing and pricing.
- International markets will experience varying degrees of price decrease based on local patent laws.
FAQs
1. What factors most influence Vyvanse’s price post-2023?
Patent expiration, generic competition, prescribing trends, and regulatory decisions are primary influences.
2. How quickly can generic versions impact Vyvanse’s price?
Typically within 12-18 months of patent expiration, assuming no delays from litigation or regulatory hurdles.
3. Will branded Vyvanse retain market share?
Possible in niche markets or via formulations with patent protections, but overall share is expected to decrease.
4. How do priced reductions affect prescribers and patients?
Lower prices generally increase accessibility and affordability, potentially leading to higher prescription volumes.
5. Are new formulations or delivery methods likely to affect pricing?
Yes, innovations like long-acting or patch formulations could command premium pricing if FDA-approved and patent-protected.
Sources
[1] IQVIA, "2022 Prescription Drug Sales," 2023.
[2] FDA Patent Data, "Vyvanse," 2023.
[3] SSR Health, "Generic Drug Price Trends," 2022.
[4] Red Book, "Average Wholesale Price Data," 2023.
[5] IMS Health, "Post-Patent Price Trends," 2022.
[6] USPTO Patent Status, "Vyvanse Patent Extensions," 2023.
